GRI | GRI Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.5050 - 0.5235
52 Week Range	0.4000 - 161.98
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	55,413
Average Volume	630,424
Shares Outstanding	2,927,710
Market Cap	1,486,984
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-10

Valuation
Profitability
Growth
Health
P/E Ratio	0.01
Forward P/E Ratio	N/A
EPS	57.07
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	GRI

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI's peers: BCLI, HOWL, EWTX, DBTX, CELC, CCCC, STTK, ELYM, PRLD, GLUE, IKNA, DSGN, XLO, PASG, HCWB, GBIO, CNTB, AVTE, ANEB, CUE

*Chart delayed

Analyzing fundamentals for GRI we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see GRI Fundamentals page.

Watching at GRI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GRI Technicals page.